The combination of high-throughput assays aimed at identifying the common mutations such as BRAF, RET, and RAS and at evaluating ctNAs can provide important information about the mutational spectrum of the tumor and guide the selection of appropriate targeted therapy. This evidence concerns the gene RET and neoplasm.